Human urotensin-II, the most potent mammalian vasoconstrictor identified to date, as a therapeutic target for the management of cardiovascular disease.
about
Is urotensin-II the new endothelin?Biochemical and functional characterization of high-affinity urotensin II receptors in rat cortical astrocytesRole of PKC in the novel synergistic action of urotensin II and angiotensin II and in urotensin II-induced vasoconstrictionUrotensin II receptor determines prognosis of bladder cancer regulating cell motility/invasion.Protein expression of urotensin II, urotensin-related peptide and their receptor in the lungs of patients with lymphangioleiomyomatosisUrotensin II alters vascular reactivity in animals subjected to volume overload.Novel G-protein-coupled receptor genes expressed in the brain: continued discovery of important therapeutic targets.Identification and pharmacological characterization of native, functional human urotensin-II receptors in rhabdomyosarcoma cell lines.Potential Clinical Implications of the Urotensin II Receptor Antagonists.Urotensin II promotes atherosclerosis in cholesterol-fed rabbits.Role of endothelins in animal models of hypertension: focus on cardiovascular protection.The orally active urotensin receptor antagonist, KR36676, attenuates cellular and cardiac hypertrophyUrotensin II in invertebrates: from structure to function in Aplysia californica.A systems biology approach to understanding the mechanisms of action of chinese herbs for treatment of cardiovascular disease.A closer look at the role of urotensin II in the metabolic syndrome.Discovery of new antagonists aimed at discriminating UII and URP-mediated biological activities: insight into UII and URP receptor activation.Effect of the urotensin-II receptor antagonist palosuran on secretion of and sensitivity to insulin in patients with Type 2 diabetes mellitus.Renal Urotensin II System Plays Roles in the Regulation of Blood Pressure in Dahl Salt-Resistant Rat.Acute Effect of Central Administration of Urotensin II on Baroreflex and Blood Pressure in Conscious Normotensive Rabbits.Plasma urotensin II and neurokinin B levels in acute myocardial infarction and stable coronary artery disease.Urotensin-II Ligands: An Overview from Peptide to Nonpeptide StructuresEndothelial nitric oxide synthase (eNOS) (Glu298Asp) and urotensin II (UTS2 S89N) gene polymorphisms in preeclampsia: prediction and correlation with severity in Egyptian females.Nonpeptidic urotensin-II receptor antagonists I: in vitro pharmacological characterization of SB-706375.Involvement of a cytoplasmic-tail serine cluster in urotensin II receptor internalization.The neuromedin B receptor antagonist, BIM-23127, is a potent antagonist at human and rat urotensin-II receptors.A new ligand for the urotensin II receptor.Molecular and pharmacological characterization of genes encoding urotensin-II peptides and their cognate G-protein-coupled receptors from the mouse and monkey.Update on the urotensinergic system: new trends in receptor localization, activation, and drug designA new therapeutic approach to erectile dysfunction: urotensin-II receptor high affinity agonist ligands.Deletion of the UT receptor gene results in the selective loss of urotensin-II contractile activity in aortae isolated from UT receptor knockout mice.Biochemical and pharmacological characterization of nuclear urotensin-II binding sites in rat heart.The vasoactive peptides urotensin II and urotensin II-related peptide regulate astrocyte activity through common and distinct mechanisms: involvement in cell proliferation.Pharmacological characterization of SB-710411 (Cpa-c[D-Cys-Pal-D-Trp-Lys-Val-Cys]-Cpa-amide), a novel peptidic urotensin-II receptor antagonist.New insight into the binding mode of peptides at urotensin-II receptor by Trp-constrained analogues of P5U and urantide.Urotensin II causes fatal circulatory collapse in anesthesized monkeys in vivo: a "vasoconstrictor" with a unique hemodynamic profile.Pharmacokinetics and pharmacodynamics of the urotensin-II receptor antagonist palosuran in healthy male subjects.Dynamic expression pattern of corticotropin-releasing hormone, urotensin I and II genes under acute salinity and temperature challenge during early development of zebrafish.Renal effects of human urotensin-II in rats with experimental congestive heart failure.Urotensin-II peptidomimetic incorporating a non-reducible 1,5-triazole disulfide bond reveals a pseudo-irreversible covalent binding mechanism to the urotensin G-protein coupled receptor.Urotensin II receptor predicts the clinical outcome of prostate cancer patients and is involved in the regulation of motility of prostate adenocarcinoma cells.
P2860
Q24672927-89A79589-3124-45F2-A58C-19E5FD503B19Q28260943-474C9651-F7A6-41AD-8433-85D38DC96D02Q28572971-D4FDD9F3-CEF7-4F67-943F-9BA6E9063B5FQ33772333-CD620CD0-DFD0-47FE-8A05-DA8B7BCF6BE6Q34001118-54BF6DDD-EC0E-43EA-ACD2-FD74606635F6Q34192302-3C22DA71-9E3D-4E23-8BC5-7336158D2488Q34837608-124C9498-7B39-4613-A451-12FA0D26501AQ35047377-96E9E747-B40D-4236-A778-45C1F6CB61A5Q35128456-1329C24C-BE70-45D1-8922-651CA760404FQ35152923-F7A318F5-3284-4826-A771-7D30DE4EEE0BQ35168394-C679FEE9-27FD-4339-8DC2-2020EBA6B064Q35538538-757B08F9-3F34-4631-916D-69802531BC3DQ36384743-0229C0C4-CE79-4D54-BFF4-AB35E543DAFFQ36396593-DB2F6C25-6351-4730-A3DE-8F8B12B09464Q36492706-2E352B97-6B37-4D77-A08E-F44FFB269595Q36781030-199E3988-80EF-4FD0-84D5-8B5F64CD3415Q37427914-BC3CEC04-3961-4798-AA2C-4B1336798C30Q37554198-2465B2DD-55E5-4884-A5B6-CEE089CE6C57Q37660867-2696D410-7922-4C82-AB95-7F8E2FDB9469Q37680436-34A49A56-7D7C-4AB4-9074-D50EAC7CE1DFQ38093584-5C523F59-9829-49DD-8B3E-73A418F72F3CQ38989978-32467195-5154-46ED-8A4A-884253DD9BB4Q40430686-AC61DB85-B0FB-4C08-BD0D-F8261855297BQ40509065-221D058C-1E72-4769-AE74-442B01613FFAQ40644520-ECFCCA55-2732-4419-845F-EECC79CD7674Q40703439-EFB8F5C0-02BE-44BB-BFE6-81CC47407172Q40735770-7DBA52D5-D379-46BF-A639-7B910F9EC29AQ41767436-D8AAB6FA-E20A-4BCF-A37F-CEBDFB4BBF41Q42139903-86ADA2D0-0DE9-4D19-80FF-8ABA6B65836BQ42215972-FE018CC6-4B5F-47DF-AAD4-25ED27383C30Q42252347-5C867A58-8FCD-4321-BB26-D09A16CCC8B6Q43146165-65F0BF68-4ECB-4F55-9CAC-53A40C5EE15EQ43263666-03759F4D-DB75-4728-819A-6A39517D20A1Q44114224-E33E0784-EE31-4FE2-B5FC-0A2CF4D2E894Q44654245-AEAA09CA-BF91-4652-A747-9F445F636419Q45922685-52073E1B-BAF9-459F-99BB-86253FC0A8FEQ46847923-066932C9-A2A4-44C1-B9D5-29F02AF7264BQ46882457-5DC45169-B694-4A21-9738-DCDD243A8A59Q50992476-02E616B3-28DA-45BB-8F7B-00A92D099CE5Q53750044-B48EF159-71F7-4892-83D7-2180D0F7A7DD
P2860
Human urotensin-II, the most potent mammalian vasoconstrictor identified to date, as a therapeutic target for the management of cardiovascular disease.
description
2000 nî lūn-bûn
@nan
2000 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Human urotensin-II, the most p ...... ent of cardiovascular disease.
@ast
Human urotensin-II, the most p ...... ent of cardiovascular disease.
@en
Human urotensin-II, the most p ...... ent of cardiovascular disease.
@nl
type
label
Human urotensin-II, the most p ...... ent of cardiovascular disease.
@ast
Human urotensin-II, the most p ...... ent of cardiovascular disease.
@en
Human urotensin-II, the most p ...... ent of cardiovascular disease.
@nl
prefLabel
Human urotensin-II, the most p ...... ent of cardiovascular disease.
@ast
Human urotensin-II, the most p ...... ent of cardiovascular disease.
@en
Human urotensin-II, the most p ...... ent of cardiovascular disease.
@nl
P1476
Human urotensin-II, the most p ...... ent of cardiovascular disease.
@en
P2093
Douglas SA
Ohlstein EH
P304
P356
10.1016/S1050-1738(00)00069-4
P577
2000-08-01T00:00:00Z